

TWiV 1220: Clinical update with Dr. Daniel Griffin
May 24, 2025
Dr. Griffin tackles the evolving landscape of FDA vaccine approvals, particularly for COVID-19 and Novavax. The discussion highlights global outbreaks of measles and flu fatalities, emphasizing the need for equitable vaccine access. Insights into long COVID reveal potential cognitive impairments and treatment options, while the impact of prolonged steroid therapy on COVID patient outcomes is examined. The hosts also respond to listener feedback about vaccine language sensitivity, stressing the importance of clear and inclusive discussions.
AI Snips
Chapters
Transcript
Episode notes
FDA Restricts COVID Vaccine Access
- FDA plans restrict COVID-19 vaccine licensing to older adults and those with risk factors.
- This move limits vaccine access for many, despite available data on benefits.
COVID's Impact on Children
- Pediatric COVID deaths exceed 150 during Omicron, contradicting mild disease claims.
- Vaccination prevents severe outcomes and reduces long COVID, evident in hospitalization data.
Novavax License Limits Usage
- Novavax vaccine licensed only for adults 65+ or high-risk 12-64 age group.
- Access denied for younger, healthy individuals, ignoring long COVID risks in this group.